183 related articles for article (PubMed ID: 29855438)
1. Zoledronic acid prevents disuse osteopenia and augments gene expression of osteoclastic differentiation markers in mice.
Vegger JB; Brüel A; Thomsen JS
J Musculoskelet Neuronal Interact; 2018 Jun; 18(2):165-175. PubMed ID: 29855438
[TBL] [Abstract][Full Text] [Related]
2. Pantoprazole, a proton pump inhibitor, does not prevent botulinum toxin induced disuse osteopenia in mice.
Vegger JB; Brüel A; Thomsen JS
J Musculoskelet Neuronal Interact; 2017 Sep; 17(3):162-175. PubMed ID: 28860418
[TBL] [Abstract][Full Text] [Related]
3. Additive effect of PTH (1-34) and zoledronate in the prevention of disuse osteopenia in rats.
Vegger JB; Nielsen ES; Brüel A; Thomsen JS
Bone; 2014 Sep; 66():287-95. PubMed ID: 24970039
[TBL] [Abstract][Full Text] [Related]
4. PTH (1-34) and growth hormone in prevention of disuse osteopenia and sarcopenia in rats.
Brent MB; Brüel A; Thomsen JS
Bone; 2018 May; 110():244-253. PubMed ID: 29475111
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis.
Little DG; Smith NC; Williams PR; Briody JN; Bilston LE; Smith EJ; Gardiner EM; Cowell CT
J Bone Miner Res; 2003 Jul; 18(7):1300-7. PubMed ID: 12854841
[TBL] [Abstract][Full Text] [Related]
6. Androgens have antiresorptive effects on trabecular disuse osteopenia independent from muscle atrophy.
Laurent MR; Jardí F; Dubois V; Schollaert D; Khalil R; Gielen E; Carmeliet G; Claessens F; Vanderschueren D
Bone; 2016 Dec; 93():33-42. PubMed ID: 27622887
[TBL] [Abstract][Full Text] [Related]
7. Zoledronate and high glucose levels influence osteoclast differentiation and bone absorption via the AMPK pathway.
Dong W; Qi M; Wang Y; Feng X; Liu H
Biochem Biophys Res Commun; 2018 Nov; 505(4):1195-1202. PubMed ID: 30322621
[TBL] [Abstract][Full Text] [Related]
8. Effect of combined treatment with zoledronic acid and propranolol on mechanical strength in an rat model of disuse osteoporosis.
Khajuria DK; Razdan R; Mahapatra DR
Rev Bras Reumatol; 2015; 55(6):501-11. PubMed ID: 25480532
[TBL] [Abstract][Full Text] [Related]
9. Disuse osteopenia induced by botulinum toxin is similar in skeletally mature young and aged female C57BL/6J mice.
Vegger JB; Brüel A; Brent MB; Thomsen JS
J Bone Miner Metab; 2018 Mar; 36(2):170-179. PubMed ID: 28365811
[TBL] [Abstract][Full Text] [Related]
10. [Additive effect of zoledronic acid and alfacalcidol in the treatment of disuse osteoporosis in rats].
Khajuria DK; Disha C; Razdan R; Mahapatra DR
Rev Bras Reumatol; 2015; 55(3):240-50. PubMed ID: 25440697
[TBL] [Abstract][Full Text] [Related]
11. Alterations in gene expression precede sarcopenia and osteopenia in botulinum toxin immobilized mice.
Vegger JB; Brüel A; Dahlgaard AF; Thomsen JS
J Musculoskelet Neuronal Interact; 2016 Dec; 16(4):355-368. PubMed ID: 27973388
[TBL] [Abstract][Full Text] [Related]
12. Low‑molecular weight fucoidan inhibits the differentiation of osteoclasts and reduces osteoporosis in ovariectomized rats.
Jin X; Zhu L; Li X; Jia J; Zhang Y; Sun X; Ma J; Liu Z; Ma X
Mol Med Rep; 2017 Feb; 15(2):890-898. PubMed ID: 28000877
[TBL] [Abstract][Full Text] [Related]
13. A soluble activin type IIA receptor mitigates the loss of femoral neck bone strength and cancellous bone mass in a mouse model of disuse osteopenia.
Lodberg A; Eijken M; van der Eerden BCJ; Okkels MW; Thomsen JS; Brüel A
Bone; 2018 May; 110():326-334. PubMed ID: 29499419
[TBL] [Abstract][Full Text] [Related]
14. Disuse-induced loss of bone mineral density and bone strength is attenuated by post-lactational bone gain in NMRI mice.
Sørensen TG; Brent MB; Thomsen JS; Brüel A
Bone; 2020 Feb; 131():115183. PubMed ID: 31794846
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
Ubellacker JM; Haider MT; DeCristo MJ; Allocca G; Brown NJ; Silver DP; Holen I; McAllister SS
Breast Cancer Res; 2017 Mar; 19(1):23. PubMed ID: 28264701
[TBL] [Abstract][Full Text] [Related]
16. Renin inhibitor aliskiren exerts beneficial effect on trabecular bone by regulating skeletal renin-angiotensin system and kallikrein-kinin system in ovariectomized mice.
Zhang Y; Wang L; Song Y; Zhao X; Wong MS; Zhang W
Osteoporos Int; 2016 Mar; 27(3):1083-1092. PubMed ID: 26439241
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of obovatol on osteoclast differentiation and bone resorption.
Kim HJ; Hong JM; Yoon HJ; Kwon BM; Choi JY; Lee IK; Kim SY
Eur J Pharmacol; 2014 Jan; 723():473-80. PubMed ID: 24334279
[TBL] [Abstract][Full Text] [Related]
18. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
Mori Y; Kasai H; Ose A; Serada M; Ishiguro M; Shiraki M; Tanigawara Y
Osteoporos Int; 2018 May; 29(5):1155-1163. PubMed ID: 29423715
[TBL] [Abstract][Full Text] [Related]
19. Effects of combined teriparatide and zoledronic acid on posterior lumbar vertebral fusion in an aged ovariectomized rat model of osteopenia.
Yishake M; Yasen M; Jiang L; Liu W; Xing R; Chen Q; Lin H; Dong J
J Orthop Res; 2018 Mar; 36(3):937-944. PubMed ID: 28796280
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.
Ottewell PD; Wang N; Brown HK; Reeves KJ; Fowles CA; Croucher PI; Eaton CL; Holen I
Clin Cancer Res; 2014 Jun; 20(11):2922-32. PubMed ID: 24687923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
